Surgery and adjuvant treatment
anastomotic fistula, pN1, tumor
ADVERSE EVENTS, TUMOR
The number of patients who underwent surgery was 46 of 50 (92%), including 2 patients treated for < 3 drug cycles because of adverse events (1 patient underwent surgery after 2 cycles, and 1 patient underwent surgery after 1 cycle of mFOLFOXIRI chemotherapy and 1 cycle of XELOX). The completion rate of adjuvant chemotherapy was 91.3%, since 4 of 46 patients who underwent surgery did not receive therapy. Only 1 patient was given capecitabine alone for adjuvant chemotherapy after recovery from an anastomotic fistula, while all the other patients accepted the XELOX adjuvant chemotherapy. The median time to start adjuvant chemotherapy is 35 (range 30–60) days after surgery. Adjuvant radiotherapy was given to 14/46 (30.4%) patients according to the opinion of MDT, all of whom presented with a distal edge of tumor < 12 cm, including 5 pN2, 1 CRM-positive, 7 pN1 and 2 pN0 patients.